Explore Stanford technologies available for licensing:

Researchers at Stanford University have discovered a novel way of treating dry age-related macular degeneration by inhibiting a causal disease target.

The Rai1-Tag knock-in allele expresses a FLAG/myc-tagged RAI1 (Rai1-Tag) before Cre recombinase exposure. Cre-mediated deletion of the floxed FLAG-myc-STOP sequence results in expression of RAI1/EGFP fusion protein (Rai1EGFP).

Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes.

Uveitis is an intraocular inflammation in the eye and represents a major cause of visual impairment and blindness worldwide.

Stanford scientists have discovered a previously unrecognized blood immune cell marker for osteoarthritis (OA) early detection.

Stanford researchers have developed REULR (Receptor Elimination by E3 Ubiquitin Ligase Recruitment), a mix and match nanobody (VHH)-based extracellular targeted protein degradation (eTPD) platform.

Rab proteins represent a large family of ras-like GTPases that regulate distinct vesicular transport events at the level of membrane targeting and/or fusion.

Mammography is the current first-line imaging technique for early breast cancer detection, however, its diagnostic accuracy is limited in women with dense breast tissue. Ultrasound is often performed as a second line test in women with dense breast tissue.

Stanford researchers have invented a novel nanobody-based platform for specific activation of bone and cartilage regeneration.

Stanford researchers have identified exercise-inducible, carboxylesterase 2 (CES2) proteins, which suppress obesity in high fat diet-fed mouse models. Generally, CES2 proteins are intracellular and localized to the endoplasmic reticulum.

Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.

The technologies described in this patent address a critically important deficit in the statistical methods available to enable comparison of outcomes measured by flow cytometry or similar, data intensive technologies.

Stanford scientists develop a method for assessing patient risk of developing postsurgical neurocognitive complications using a combination of biomarkers. This method will ensure improved interventions and treatment outcomes.

Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.

Stanford researchers have developed a method which can simultaneously observe two positron emitting isotopes using two distinct molecular probes and a modified PET scanner. This system enables the simultaneous observation of two different molecular processes.